The Critical Challenge in Innovation
Stroke is the second-leading cause of death and the third-leading cause of combined death and disability worldwide. Despite global prevention efforts, stroke incidence continues to rise. Rapid and accurate diagnosis remains essential to prevent irreversible brain damage and death.
Our Innovative Solution
Galaxy CCRO is developing a point-of-care blood test capable of determining stroke onset, unlocking access to time-sensitive thrombolytic therapies such as TPA for a significantly larger patient population.
Investing in Galaxy CCRO
Clinical Advancement
More than 15 million strokes occur each year globally, creating urgent demand for faster and more reliable diagnostic solutions.
Strategic Partnerships
Galaxy CCRO holds a licensed technology agreement with Proteome Sciences, harnessing world-class expertise in proteomics and biomarker discovery.
Experienced Leadership
Our leadership team brings deep expertise across emergency medicine, proteomics, clinical research, and business development, ensuring disciplined execution and scalable growth.
Join Us in Making a Difference
Invest in the future of stroke care. Supporting Galaxy CCRO means advancing life-saving diagnostic technology and delivering real impact for patients worldwide.